The Metabolic Research Stack combines three compounds with complementary mechanisms targeting different aspects of metabolic function: AOD-9604 (selective fat mobilization through hGH C-terminal fragment activity), Semaglutide (GLP-1 receptor agonism and appetite regulation), and NAD+ (mitochondrial energy metabolism and cellular energetics). Each operates through distinct pathways, providing layered coverage of the metabolic landscape.
AOD-9604 is the C-terminal fragment of human growth hormone (amino acids 177–191 + N-terminal Tyr), engineered to retain hGH's fat-metabolism activity while eliminating its diabetogenic and mitogenic effects. This selective profile makes it a targeted research tool for studying lipolysis and fat oxidation pathways without the full hGH receptor activation noise.
AOD-9604 promotes fat breakdown through β-3 adrenergic receptor activation and cAMP-mediated lipolysis in adipocytes — a distinct mechanism from GLP-1 agonist-driven fat loss (which operates primarily through appetite reduction and gastric slowing). This mechanistic independence is the research rationale for combining them: complementary pathways, not redundant ones.
AOD-9604 reached Phase 3 clinical trials in obesity before Metabolic Pharmaceuticals discontinued the program on commercial grounds, and received GRAS status from the FDA in 2014 — a higher regulatory reference point than most research peptides carry.
Semaglutide provides the incretin-mediated component of the stack: GLP-1 receptor engagement drives glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and CNS appetite reduction. The STEP 1 trial demonstrated 14.9% mean weight reduction over 68 weeks in non-diabetic obesity.
In combination with AOD-9604, Semaglutide addresses the appetite and insulin signaling dimensions while AOD-9604 targets direct adipocyte lipolysis — representing parallel pathways to the same metabolic research endpoint.
NAD+ occupies the foundational metabolic role in this stack: it is required for mitochondrial electron transport (supporting cellular energy production), sirtuin activity (regulating metabolic gene expression), and PARP-mediated DNA repair (maintaining cellular integrity under metabolic stress). In aged or metabolically stressed cells, NAD+ depletion impairs all of these functions simultaneously.
Research from the Sinclair and Verdin labs demonstrates that NAD+ restoration in metabolically compromised cells improves mitochondrial function, insulin sensitivity, and stress response — providing the cellular bioenergetic support that allows the other metabolic compounds to operate in an optimized cellular environment.
The three compounds cover metabolic biology at three distinct levels:
Heffernan et al. (J Endocrinol, 2001): AOD-9604 demonstrated direct lipolytic activity in adipose tissue culture and significant fat mass reduction in obese Zucker rat models — confirming the fat-metabolism selectivity that makes it pharmacologically distinct from full hGH. Journal of Endocrinology, 2001.
STEP 1 Trial (Wilding et al., NEJM 2021): Semaglutide 2.4mg weekly → 14.9% mean weight reduction at 68 weeks. Best-in-class GLP-1 monoagonist data that established semaglutide as the reference compound for incretin-based metabolic research. NEJM, 2021.
Gomes et al. (Cell, 2013): NAD+ restoration reverses mitochondrial dysfunction and restores more youthful mitochondrial gene expression in aged mice — the foundational paper for NAD+ supplementation as a metabolic intervention. Cell, 2013.
AOD-9604 · Semaglutide · NAD+ · All ≥99% purity · Third-party tested · COA included
Shop Metabolic Compounds →